Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation will feature their clinical asset CTIM-76, a Claudin 6 x CD3 bispecific antibody.
The poster, titled 'Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6,' will be presented on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB of the George R. Brown Convention Center in Houston, TX. The authors of the presentation are Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.
Context Therapeutics Inc. (Nasdaq: CNTX), un'azienda biofarmaceutica focalizzata sugli engagers delle cellule T per tumori solidi, ha annunciato una presentazione di poster al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC). La presentazione metterà in evidenza il loro asset clinico CTIM-76, un anticorpo bispecifico Claudin 6 x CD3.
Il poster, intitolato 'Determinazione della dose iniziale negli esseri umani dell'anticorpo bispecifico CTIM-76 che indirizza le cellule T e targeting Claudin 6,' sarà presentato sabato 9 novembre 2024, alle 9:00 a.m. CDT nelle Sale Espositive AB del George R. Brown Convention Center a Houston, TX. Gli autori della presentazione sono Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts ed Eric Butz.
Context Therapeutics Inc. (Nasdaq: CNTX), una empresa biofarmacéutica centrada en los activadores de células T para tumores sólidos, ha anunciado una presentación de póster en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC). La presentación destacará su activo clínico CTIM-76, un anticuerpo bispecífico Claudin 6 x CD3.
El póster, titulado 'Determinación de la primera dosis en humanos del anticuerpo bispecífico que redirige células T CTIM-76 dirigido a Claudin 6,' será presentado el sábados 9 de noviembre de 2024, a las 9:00 a.m. CDT en los Salones de Exhibición AB del Centro de Convenciones George R. Brown en Houston, TX. Los autores de la presentación son Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts y Eric Butz.
Context Therapeutics Inc.(Nasdaq: CNTX)는 고형종양을 위한 T세포 결합제에 집중하는 생명공학 회사로, 암 면역 치료 학회(SITC)의 제39회 연례 회의에서 포스터 발표를 발표했습니다. 이 발표에서는 그들의 임상 자산 CTIM-76, Claudin 6 x CD3 이중특이항체가 소개될 것입니다.
'Claudin 6을 표적하는 T세포 재지정 이중특이항체 CTIM-76의 사람 대상 첫 용량 결정'이라는 제목의 포스터는 2024년 11월 9일 토요일 오전 9:00 CDT에 휴스턴, TX에 위치한 George R. Brown 컨벤션 센터의 AB 전시 홀에서 발표될 것입니다. 발표 저자는 Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric Butz입니다.
Context Therapeutics Inc. (Nasdaq: CNTX), une société bio-pharmaceutique axée sur les activateurs de cellules T pour les tumeurs solides, a annoncé une présentation d'affiche lors de la 39ème Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC). La présentation mettra en avant leur actif clinique CTIM-76, un anticorps bispécifique Claudin 6 x CD3.
L'affiche, intitulée 'Détermination de la première dose chez l'homme de l'anticorps bispécifique CTIM-76 redirigeant les cellules T ciblant Claudin 6,' sera présentée le samedi 9 novembre 2024, à 9h00 CDT dans les halls d'exposition AB du George R. Brown Convention Center à Houston, TX. Les auteurs de la présentation sont Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts et Eric Butz.
Context Therapeutics Inc. (Nasdaq: CNTX), ein biopharmazeutisches Unternehmen, das sich auf T-Zell-Engager für solide Tumore spezialisiert hat, hat eine Posterpräsentation auf dem 39. Jahrestreffen der Society for Immunotherapy of Cancer (SITC) angekündigt. In der Präsentation wird ihr klinisches Asset CTIM-76, ein bispezifischer Antikörper Claudin 6 x CD3, vorgestellt.
Das Poster mit dem Titel 'Bestimmung der ersten Dosis beim Menschen des T-Zell-umleitenden bispezifischen Antikörpers CTIM-76, der auf Claudin 6 abzielt' wird am Samstag, den 9. November 2024, um 9:00 Uhr CDT in den Ausstellungsräumen AB des George R. Brown Convention Centers in Houston, TX, präsentiert. Die Autoren der Präsentation sind Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts und Eric Butz.
- Poster presentation at a major cancer immunotherapy conference (SITC)
- Showcasing clinical asset CTIM-76, a bispecific antibody for solid tumors
- None.
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Presentation Details:
| Title: | Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6 |
| Authors: | Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric Butz |
| Abstract Number: | 1288 |
| Date and Time: | Saturday, November 9, 2024, 9:00a.m. CDT |
| Location: | Exhibit Halls AB |
For more information and to view the abstract, visit the SITC 39th Annual Meeting website.
About CTIM-76
CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain SITC presenters to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com
FAQ
What is Context Therapeutics presenting at SITC 39th Annual Meeting?
When and where is Context Therapeutics (CNTX) presenting at SITC 2024?
Who are the authors of Context Therapeutics' SITC 2024 poster presentation?
What is the focus of Context Therapeutics' (CNTX) clinical asset CTIM-76?
